Genentech, a member of the Roche Group (RHHBY), Tuesday reported positive top line data from overall survival (OS) analysis of the Phase 3 INAVO120 study investigating Itovebi in combination with Ibrance and Fulvestrant for people with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, endocrine-resistant breast cancer.
Primary analysis showed the Itovebi-based regimen reached statistical significance, more than doubling progression-free survival in this patient population.
Previously, data from the primary analysis showed that Itovebi-based regimen reduced the risk of disease worsening or death by 57 percent compared with palbociclib and fulvestrant alone.
The U.S. Food and Drug Administration (FDA) approved the Itovebi-based regimen in October last year for the treatment of adults with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer.
The company noted that these OS results builds upon the previously reported primary analysis, which showed that the Itovebi-based regimen reduced the risk of disease worsening or death by 57% compared with palbociclib and fulvestrant alone
Itovebi is currently being investigated in four Phase 3 studies including INAVO120, INAVO121, INAVO122, and INAVO123 in PIK3CA-mutated locally advanced or metastatic breast cancer in various combinations.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.